Chugai Pharmaceutical has entered into an agreement with Taisho Pharmaceutical to co-develop and co-market ED-71, an activated vitamin D derivative, which Chugai is currently developing in Japan for the treatment of osteoporosis.

Arena Pharmaceuticals has announced that Taisho Pharmaceutical has started a Phase I clinical trial of a drug candidate under a GPCR-focused partnership with Arena to develop compounds to treat psychiatric disorders.

SAN DIEGO and TOKYO, Sept. 27 /PRNewswire/ -- BrainCells Inc. (BCI) and Taisho Pharmaceutical Co., Ltd. (Taisho) today announced that BCI has in-licensed a novel development program from Taisho that BCI will develop for central nervous system (CNS) indications, including mood disorders.

Research and Markets (http://www.researchandmarkets.com/reports/c60448) has announced the addition of Analyzing the Global Pharmaceutical Industry to their offering. The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs.

Eli Lilly and Company has terminated its licensing agreement for Taisho Pharmaceutical's TS-021 after the investigational treatment for type 2 diabetes failed to meet certain criteria set by Lilly in a preclinical trial.